

PEPTIDE

AOD-9604 (hGH 176-191)

Modified C-terminal fragment of hGH (residues 176-191); preclinically lipolytic but failed to demonstrate clinical weight loss in Phase 2 trials.

BIOGATE · AMBER POSTERIOR 68.7% MW 1815.1 16AA

SEQUENCE

YLRIVQCRSVEGSCGF

Modifications: disulfide C7-C15; tyrosine-extended hGH C-terminal fragment

PDA-V1 chain of custody

Outer hash

b2cc8af4b3cc8c87b4cc8e1ab5cc8fadaecc84a8afcc863bb0cc87c

Merkle root

d4fcaa41d3fca8aed2fca71bd1fca588d8fcb08dd7fcae-fad6fcad67d5fcabd4

Inputs

a2f05374a3f05507a4f0569aa5f0582d9ef04d289ff04ebba0f0504

TEE attestation

c99d6cf3c89d6b60cb9d7019ca9d6e86cd9d733fcc9d71accf9d7665ce9d74d2

Living Outcome Oracle

± 51.8

² =23.6

P(success) = 68.7%

95% CI [56.7%, 80.7%]

Seven-rule export gate

6 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

BLOCK REASONS

⊗ Grade A or B citation present on the core claim

Citations

GRADE C

2001 · Endocrinology

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism

Heffernan M et al.

PMID 11796512